{"id":"nitrendipine","rwe":[{"pmid":"41563468","year":"2026","title":"Na(+) Uptake Triggered in Adrenal Chromaffin Cells by a 5-ns Electric Pulse is Facilitated by Ca(2+) Influx Via an L-Type-Like Ca(2+) Channel Independent of Changes in Membrane Potential.","finding":"","journal":"The Journal of membrane biology","studyType":"Clinical Study"},{"pmid":"41363682","year":"2026","title":"Pharmacogenomics-Guided Precision Therapy for Chronic Kidney Disease with Resistant Hypertension: A Prospective Cohort Study.","finding":"","journal":"Kidney & blood pressure research","studyType":"Clinical Study"},{"pmid":"41241198","year":"2026","title":"Deoxynivalenol-induced anorexia is mediated by brain-gut peptides through CaSR-TRPM5 signaling axis.","finding":"","journal":"Toxicon : official journal of the International Society on Toxinology","studyType":"Clinical Study"},{"pmid":"41163212","year":"2025","title":"QbD-driven RP-HPLC method for the simultaneous analysis of dihydropyridines calcium channel blockers in pharmaceuticals.","finding":"","journal":"BMC chemistry","studyType":"Clinical Study"},{"pmid":"41064448","year":"2025","title":"Evaluation the inhibitory effect of nicardipine on the metabolism of quetiapine.","finding":"","journal":"Frontiers in pharmacology","studyType":"Clinical Study"}],"tags":[{"label":"nitrendipine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Voltage-dependent L-type calcium channel subunit alpha-1C","category":"target"},{"label":"CACNA1C","category":"gene"},{"label":"CACNA1D","category":"gene"},{"label":"KCNN4","category":"gene"},{"label":"C08CA08","category":"atc"},{"label":"Active","category":"status"},{"label":"Antihypertensive Agents","category":"pharmacology"},{"label":"Calcium Channel Blockers","category":"pharmacology"},{"label":"Calcium-Regulating Hormones and Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Membrane Transport Modulators","category":"pharmacology"},{"label":"Vasodilator Agents","category":"pharmacology"}],"phase":"discontinued","safety":{"safetySignals":[{"llr":147.371,"date":"","count":70,"signal":"Product prescribing error","source":"DrugCentral FAERS","actionTaken":"Reported 70 times (LLR=147)"},{"llr":138.839,"date":"","count":136,"signal":"General physical health deterioration","source":"DrugCentral FAERS","actionTaken":"Reported 136 times (LLR=139)"},{"llr":131.153,"date":"","count":25,"signal":"Renal cyst haemorrhage","source":"DrugCentral FAERS","actionTaken":"Reported 25 times (LLR=131)"},{"llr":113.418,"date":"","count":23,"signal":"Intraductal papillary mucinous neoplasm","source":"DrugCentral FAERS","actionTaken":"Reported 23 times (LLR=113)"},{"llr":101.846,"date":"","count":18,"signal":"Vena cava injury","source":"DrugCentral FAERS","actionTaken":"Reported 18 times (LLR=102)"},{"llr":101.264,"date":"","count":19,"signal":"SARS-CoV-2 antibody test positive","source":"DrugCentral FAERS","actionTaken":"Reported 19 times (LLR=101)"},{"llr":100.918,"date":"","count":25,"signal":"Rectal prolapse","source":"DrugCentral FAERS","actionTaken":"Reported 25 times (LLR=101)"},{"llr":95.884,"date":"","count":25,"signal":"Carotid arteriosclerosis","source":"DrugCentral FAERS","actionTaken":"Reported 25 times (LLR=96)"},{"llr":95.369,"date":"","count":159,"signal":"Dizziness","source":"DrugCentral FAERS","actionTaken":"Reported 159 times (LLR=95)"},{"llr":94.211,"date":"","count":90,"signal":"Syncope","source":"DrugCentral FAERS","actionTaken":"Reported 90 times (LLR=94)"},{"llr":94.1,"date":"","count":19,"signal":"Abdominal wall haemorrhage","source":"DrugCentral FAERS","actionTaken":"Reported 19 times (LLR=94)"},{"llr":93.247,"date":"","count":25,"signal":"Delayed graft function","source":"DrugCentral FAERS","actionTaken":"Reported 25 times (LLR=93)"},{"llr":91.592,"date":"","count":16,"signal":"Vascular anastomotic haemorrhage","source":"DrugCentral FAERS","actionTaken":"Reported 16 times (LLR=92)"},{"llr":85.605,"date":"","count":15,"signal":"Perineal cyst","source":"DrugCentral FAERS","actionTaken":"Reported 15 times (LLR=86)"},{"llr":81.387,"date":"","count":21,"signal":"Aortic dilatation","source":"DrugCentral FAERS","actionTaken":"Reported 21 times (LLR=81)"}],"commonSideEffects":[{"effect":"Product prescribing error","drugRate":"LLR 147","severity":"common"},{"effect":"General physical health deterioration","drugRate":"LLR 139","severity":"common"},{"effect":"Renal cyst haemorrhage","drugRate":"LLR 131","severity":"common"},{"effect":"Intraductal papillary mucinous neoplasm","drugRate":"LLR 113","severity":"common"},{"effect":"Vena cava injury","drugRate":"LLR 102","severity":"common"},{"effect":"SARS-CoV-2 antibody test positive","drugRate":"LLR 101","severity":"common"},{"effect":"Rectal prolapse","drugRate":"LLR 101","severity":"common"},{"effect":"Carotid arteriosclerosis","drugRate":"LLR 96","severity":"common"},{"effect":"Dizziness","drugRate":"LLR 95","severity":"common"},{"effect":"Syncope","drugRate":"LLR 94","severity":"common"},{"effect":"Abdominal wall haemorrhage","drugRate":"LLR 94","severity":"common"},{"effect":"Delayed graft function","drugRate":"LLR 93","severity":"common"},{"effect":"Vascular anastomotic haemorrhage","drugRate":"LLR 92","severity":"common"},{"effect":"Perineal cyst","drugRate":"LLR 86","severity":"common"},{"effect":"Aortic dilatation","drugRate":"LLR 81","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"nitrepin","offLabel":[],"synonyms":["nitrendipine","nitrendipin","nitrepin"],"timeline":[{"date":"1985-01-01","type":"positive","source":"DrugCentral","milestone":"YEAR INTRODUCED approval"}],"aiSummary":"Nitrendipine, also known as NITRENDIPINE, is a small molecule drug that targets the voltage-dependent L-type calcium channel subunit alpha-1C. It belongs to the drug class of nitrendipine and works by inhibiting the influx of calcium ions into smooth muscle cells, leading to vasodilation. Nitrendipine is used to treat hypertension, but its commercial status and approved indications are unknown. The drug has a half-life of 8.2 hours and bioavailability of 16%. Key safety considerations include its potential effects on blood pressure and calcium levels.","approvals":[{"date":"1985-01-01","orphan":false,"company":"","regulator":"YEAR INTRODUCED"}],"brandName":"Nitrepin","ecosystem":[],"mechanism":{"target":"Voltage-dependent calcium channel gamma-1 subunit, ATP-binding cassette sub-family G member 2, Adenosine receptor A3","targets":[{"gene":"CACNA1C","source":"DrugCentral","target":"Voltage-dependent L-type calcium channel subunit alpha-1C","protein":"Voltage-dependent L-type calcium channel subunit alpha-1C"},{"gene":"CACNA1D","source":"DrugCentral","target":"Voltage-dependent L-type calcium channel subunit alpha-1D","protein":"Voltage-dependent L-type calcium channel subunit alpha-1D"},{"gene":"KCNN4","source":"DrugCentral","target":"Intermediate conductance calcium-activated potassium channel protein 4","protein":"Intermediate conductance calcium-activated potassium channel protein 4"},{"gene":"CYP2C9","source":"DrugCentral","target":"Cytochrome P450 2C9","protein":"Cytochrome P450 2C9"},{"gene":"CACNA1F","source":"DrugCentral","target":"Voltage-dependent L-type calcium channel subunit alpha-1F","protein":"Voltage-dependent L-type calcium channel subunit alpha-1F"},{"gene":"TTR","source":"DrugCentral","target":"Transthyretin","protein":"Transthyretin"},{"gene":"PDE1C","source":"DrugCentral","target":"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C","protein":"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C"},{"gene":"CYP2C19","source":"DrugCentral","target":"Cytochrome P450 2C19","protein":"Cytochrome P450 2C19"},{"gene":"ADORA3","source":"DrugCentral","target":"Adenosine receptor A3","protein":"Adenosine receptor A3"},{"gene":"CACNA1H","source":"DrugCentral","target":"Voltage-dependent T-type calcium channel subunit alpha-1H","protein":"Voltage-dependent T-type calcium channel subunit alpha-1H"}],"modality":"Small Molecule","drugClass":"nitrendipine","explanation":"Imagine your blood vessels are like roads in your body. When they're narrow, it's harder for blood to flow. Nitrendipine helps to widen these roads by blocking the flow of calcium ions, which causes the muscles in the blood vessel walls to relax. This makes it easier for blood to flow and helps to lower blood pressure.","oneSentence":"Nitrendipine works by blocking calcium channels in blood vessel walls, causing them to relax and widen.","technicalDetail":"Nitrendipine selectively inhibits the L-type calcium channel subunit alpha-1C, which is responsible for the influx of calcium ions into smooth muscle cells, leading to vasodilation and a subsequent decrease in blood pressure."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Nitrendipine","title":"Nitrendipine","extract":"Nitrendipine is a dihydropyridine calcium channel blocker. It is used in the treatment of primary (essential) hypertension to decrease blood pressure and can reduce the cardiotoxicity of cocaine."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1947","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=NITRENDIPINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NITRENDIPINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Nitrendipine","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T15:09:13.957509","biosimilars":[],"competitors":[{"drugName":"amlodipine","drugSlug":"amlodipine","fdaApproval":"1992-07-31","patentExpiry":"Feb 24, 2041","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"felodipine","drugSlug":"felodipine","fdaApproval":"1991-07-25","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"isradipine","drugSlug":"isradipine","fdaApproval":"1990-12-20","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"nicardipine","drugSlug":"nicardipine","fdaApproval":"1988-12-21","patentExpiry":"Dec 26, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"nifedipine","drugSlug":"nifedipine","fdaApproval":"1981-12-31","genericCount":24,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"nimodipine","drugSlug":"nimodipine","fdaApproval":"1988-12-28","patentExpiry":"Apr 16, 2038","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"nisoldipine","drugSlug":"nisoldipine","fdaApproval":"1995-02-02","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"clevidipine","drugSlug":"clevidipine","fdaApproval":"2008-08-01","patentExpiry":"Oct 10, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"celecoxib","drugSlug":"celecoxib","fdaApproval":"1998-12-31","patentExpiry":"May 27, 2036","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"nitrendipine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"amlodipine","brandName":"amlodipine","genericName":"amlodipine","approvalYear":"1992","relationship":"same-class"},{"drugId":"felodipine","brandName":"felodipine","genericName":"felodipine","approvalYear":"1991","relationship":"same-class"},{"drugId":"isradipine","brandName":"isradipine","genericName":"isradipine","approvalYear":"1990","relationship":"same-class"},{"drugId":"nicardipine","brandName":"nicardipine","genericName":"nicardipine","approvalYear":"1988","relationship":"same-class"},{"drugId":"nifedipine","brandName":"nifedipine","genericName":"nifedipine","approvalYear":"1981","relationship":"same-class"},{"drugId":"nimodipine","brandName":"nimodipine","genericName":"nimodipine","approvalYear":"1988","relationship":"same-class"},{"drugId":"nisoldipine","brandName":"nisoldipine","genericName":"nisoldipine","approvalYear":"1995","relationship":"same-class"},{"drugId":"clevidipine","brandName":"clevidipine","genericName":"clevidipine","approvalYear":"2008","relationship":"same-class"},{"drugId":"celecoxib","brandName":"celecoxib","genericName":"celecoxib","approvalYear":"1998","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":["Post-stroke Pneumonia"],"enrollment":13656,"completionDate":"2026-08-19"},{"nctId":"NCT00751829","phase":"PHASE3","title":"Isolated Systolic Hypertension in the Elderly and Very Elderly","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2003-07","conditions":["Isolated Systolic Hypertension"],"enrollment":417,"completionDate":"2005-02"},{"nctId":"NCT04931108","phase":"PHASE4","title":"The Effect of Nitrendipine/Atenolol Combination on Blood Pressure Variability.","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2021-09-27","conditions":["Hypertension"],"enrollment":32,"completionDate":"2023-06"},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":["Hypertension","COVID-19"],"enrollment":2414,"completionDate":"2021-12-01"},{"nctId":"NCT04371874","phase":"NA","title":"The Standardized Management of Hypertension in Rural Shaanxi","status":"COMPLETED","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2014-01","conditions":["Hypertension"],"enrollment":1210,"completionDate":"2019-02"},{"nctId":"NCT02088450","phase":"PHASE2","title":"Systolic Hypertension in Europe Placebo-Controlled Trial","status":"TERMINATED","sponsor":"KU Leuven","startDate":"1990-02","conditions":["Isolated Systolic Hypertension"],"enrollment":4695,"completionDate":"1997-02"},{"nctId":"NCT00892892","phase":"PHASE4","title":"Sympathetic Nerve Activity in Renal Failure","status":"WITHDRAWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2009-11","conditions":["Chronic Kidney Disease","Hypertension"],"enrollment":0,"completionDate":"2011-06"},{"nctId":"NCT02217852","phase":"PHASE4","title":"Treatment of Hypertension in Tibetan Adult Population","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2014-08","conditions":["Hypertension"],"enrollment":800,"completionDate":"2016-07"},{"nctId":"NCT01074281","phase":"","title":"An Observational Study to Examine the Patients With Isolated Systolic Hypertonia (ISH) Under Therapy With Eneas® (NIS ENEAS ISH)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2008-06","conditions":["Hypertension"],"enrollment":2065,"completionDate":"2009-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NUI":"N0000167238","NDDF":"005383","UNII":"9B627AW319","CHEBI":"CHEBI:7582","INN_ID":"4739","RXNORM":"7441","UMLSCUI":"C0028127","ChEMBL_ID":"CHEMBL475534","KEGG_DRUG":"D00629","DRUGBANK_ID":"DB01054","PUBCHEM_CID":"4507","SNOMEDCT_US":"444757009","IUPHAR_LIGAND_ID":"2334","MESH_DESCRIPTOR_UI":"D009568"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"8.2 hours","clearance":"25.0 mL/min/kg","bioavailability":"16%","fractionUnbound":"0.02%","volumeOfDistribution":"6.1 L/kg"},"publicationCount":0,"therapeuticAreas":["Hematology"],"atcClassification":{"source":"DrugCentral","atcCode":"C08CA08","allCodes":["C08CA08","C09BB06"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Jan 21","pmid":"41563468","title":"Na(+) Uptake Triggered in Adrenal Chromaffin Cells by a 5-ns Electric Pulse is Facilitated by Ca(2+) Influx Via an L-Type-Like Ca(2+) Channel Independent of Changes in Membrane Potential.","journal":"The Journal of membrane biology"},{"date":"2026","pmid":"41363682","title":"Pharmacogenomics-Guided Precision Therapy for Chronic Kidney Disease with Resistant Hypertension: A Prospective Cohort Study.","journal":"Kidney & blood pressure research"},{"date":"2026 Jan","pmid":"41241198","title":"Deoxynivalenol-induced anorexia is mediated by brain-gut peptides through CaSR-TRPM5 signaling axis.","journal":"Toxicon : official journal of the International Society on Toxinology"},{"date":"2025 Oct 29","pmid":"41163212","title":"QbD-driven RP-HPLC method for the simultaneous analysis of dihydropyridines calcium channel blockers in pharmaceuticals.","journal":"BMC chemistry"},{"date":"2025","pmid":"41064448","title":"Evaluation the inhibitory effect of nicardipine on the metabolism of quetiapine.","journal":"Frontiers in pharmacology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"YEAR INTRODUCED","status":"approved","approval_date":"1985-01-01T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}